Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Constitutive activation of RAS/MAPK pathway cooperates with trisomy 21 and is therapeutically exploitable in Down syndrome B-cell leukemia.

Laurent AP, Siret A, Ignacimouttou C, Panchal K, Diop M, Jenni S, Tsai YC, Roos-Weil D, Aid Z, Prade N, Lagarde S, Plassard D, Pierron G, Daudigeos E, Lecluse Y, Droin N, Bornhauser BC, Cheung LC, Crispino JD, Gaudry M, Bernard OA, Macintyre E, Barin Bonnigal C, Kotecha RS, Geoerger B, Ballerini P, Bourquin JP, Delabesse E, Mercher T, Malinge S.

Clin Cancer Res. 2020 Mar 27. pii: clincanres.3519.2019. doi: 10.1158/1078-0432.CCR-19-3519. [Epub ahead of print]

PMID:
32220889
2.

Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant-associated ALCL.

Laurent C, Nicolae A, Laurent C, Le Bras F, Haioun C, Fataccioli V, Amara N, Adélaïde J, Guille A, Schiano JM, Tesson B, Traverse-Glehen A, Chenard MP, Mescam L, Moreau A, Chassagne-Clement C, Somja J, Escudié F, André M, Martin N, Lacroix L, Lemonnier F, Hamy AS, Reyal F, Bannier M, Oberic L, Prade N, Frénois FX, Beldi-Ferchiou A, Delfau-Larue MH, Bouabdallah R, Birnbaum D, Brousset P, Xerri L, Gaulard P.

Blood. 2020 Jan 30;135(5):360-370. doi: 10.1182/blood.2019001904.

3.

Outcome of relapsed/refractory AML patients with IDH1R132 mutations in real life before the era of IDH1 inhibitors.

Largeaud L, Bertoli S, Bérard E, Dufrechou S, Prade N, Gadaud N, Tavitian S, Bories P, Luquet I, Sarry A, Mas V, Huguet F, Delabesse E, Récher C.

Leuk Lymphoma. 2020 Feb;61(2):473-476. doi: 10.1080/10428194.2019.1668937. Epub 2019 Sep 30. No abstract available.

PMID:
31566052
4.

Outcome of AML patients with IDH2 mutations in real world before the era of IDH2 inhibitors.

Largeaud L, Bérard E, Bertoli S, Dufrechou S, Prade N, Gadaud N, Tavitian S, Bories P, Luquet I, Sarry A, De Mas V, Huguet F, Delabesse E, Récher C.

Leuk Res. 2019 Jun;81:82-87. doi: 10.1016/j.leukres.2019.04.010. Epub 2019 Apr 27.

PMID:
31055247
5.

PAX5-ELN oncoprotein promotes multistep B-cell acute lymphoblastic leukemia in mice.

Jamrog L, Chemin G, Fregona V, Coster L, Pasquet M, Oudinet C, Rouquié N, Prade N, Lagarde S, Cresson C, Hébrard S, Nguyen Huu NS, Bousquet M, Quelen C, Brousset P, Mancini SJC, Delabesse E, Khamlichi AA, Gerby B, Broccardo C.

Proc Natl Acad Sci U S A. 2018 Oct 9;115(41):10357-10362. doi: 10.1073/pnas.1721678115. Epub 2018 Sep 26.

6.

PAX5A and PAX5B isoforms are both efficient to drive B cell differentiation.

Cresson C, Péron S, Jamrog L, Rouquié N, Prade N, Dubois M, Hébrard S, Lagarde S, Gerby B, Mancini SJC, Cogné M, Delabesse E, Delpy L, Broccardo C.

Oncotarget. 2018 Aug 28;9(67):32841-32854. doi: 10.18632/oncotarget.26003. eCollection 2018 Aug 28.

7.

Bone marrow sites differently imprint dormancy and chemoresistance to T-cell acute lymphoblastic leukemia.

Cahu X, Calvo J, Poglio S, Prade N, Colsch B, Arcangeli ML, Leblanc T, Petit A, Baleydier F, Baruchel A, Landman-Parker J, Junot C, Larghero J, Ballerini P, Delabesse E, Uzan B, Pflumio F.

Blood Adv. 2017 Sep 8;1(20):1760-1772. doi: 10.1182/bloodadvances.2017004960. eCollection 2017 Sep 12.

8.

NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis.

Struski S, Lagarde S, Bories P, Puiseux C, Prade N, Cuccuini W, Pages MP, Bidet A, Gervais C, Lafage-Pochitaloff M, Roche-Lestienne C, Barin C, Penther D, Nadal N, Radford-Weiss I, Collonge-Rame MA, Gaillard B, Mugneret F, Lefebvre C, Bart-Delabesse E, Petit A, Leverger G, Broccardo C, Luquet I, Pasquet M, Delabesse E.

Leukemia. 2017 Mar;31(3):565-572. doi: 10.1038/leu.2016.267. Epub 2016 Oct 3.

PMID:
27694926
9.

Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia.

Le Bris Y, Struski S, Guièze R, Rouvellat C, Prade N, Troussard X, Tournilhac O, Béné MC, Delabesse E, Ysebaert L.

Hematol Oncol. 2017 Dec;35(4):664-670. doi: 10.1002/hon.2349. Epub 2016 Sep 28.

PMID:
27678008
10.

CHK1 as a therapeutic target to bypass chemoresistance in AML.

David L, Fernandez-Vidal A, Bertoli S, Grgurevic S, Lepage B, Deshaies D, Prade N, Cartel M, Larrue C, Sarry JE, Delabesse E, Cazaux C, Didier C, Récher C, Manenti S, Hoffmann JS.

Sci Signal. 2016 Sep 13;9(445):ra90. doi: 10.1126/scisignal.aac9704.

PMID:
27625304
11.

High frequency of GATA2 mutations in patients with mild chronic neutropenia evolving to MonoMac syndrome, myelodysplasia, and acute myeloid leukemia.

Pasquet M, Bellanné-Chantelot C, Tavitian S, Prade N, Beaupain B, Larochelle O, Petit A, Rohrlich P, Ferrand C, Van Den Neste E, Poirel HA, Lamy T, Ouachée-Chardin M, Mansat-De Mas V, Corre J, Récher C, Plat G, Bachelerie F, Donadieu J, Delabesse E.

Blood. 2013 Jan 31;121(5):822-9. doi: 10.1182/blood-2012-08-447367. Epub 2012 Dec 6.

12.

RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation.

Ballerini P, Struski S, Cresson C, Prade N, Toujani S, Deswarte C, Dobbelstein S, Petit A, Lapillonne H, Gautier EF, Demur C, Lippert E, Pages P, Mansat-De Mas V, Donadieu J, Huguet F, Dastugue N, Broccardo C, Perot C, Delabesse E.

Leukemia. 2012 Nov;26(11):2384-9. doi: 10.1038/leu.2012.109. Epub 2012 Apr 19.

PMID:
22513837
13.

ALK+ALCLs induce cutaneous, HMGB-1-dependent IL-8/CXCL8 production by keratinocytes through NF-κB activation.

Dejean E, Foisseau M, Lagarrigue F, Lamant L, Prade N, Marfak A, Delsol G, Giuriato S, Gaits-Iacovoni F, Meggetto F.

Blood. 2012 May 17;119(20):4698-707. doi: 10.1182/blood-2011-10-386011. Epub 2012 Mar 6.

PMID:
22394598
14.

The gene expression profile of phosphoantigen-specific human γδ T lymphocytes is a blend of αβ T-cell and NK-cell signatures.

Pont F, Familiades J, Déjean S, Fruchon S, Cendron D, Poupot M, Poupot R, L'faqihi-Olive F, Prade N, Ycart B, Fournié JJ.

Eur J Immunol. 2012 Jan;42(1):228-40. doi: 10.1002/eji.201141870. Epub 2011 Dec 2.

15.

Critical features of FAK-expressing AML bone marrow microenvironment through leukemia stem cell hijacking of mesenchymal stromal cells.

Despeaux M, Labat E, Gadelorge M, Prade N, Bertrand J, Demur C, Recher C, Bonnevialle P, Payrastre B, Bourin P, Racaud-Sultan C.

Leukemia. 2011 Nov;25(11):1789-93. doi: 10.1038/leu.2011.145. Epub 2011 Jun 7. No abstract available.

PMID:
21647157
16.

Identification of a transforming MYB-GATA1 fusion gene in acute basophilic leukemia: a new entity in male infants.

Quelen C, Lippert E, Struski S, Demur C, Soler G, Prade N, Delabesse E, Broccardo C, Dastugue N, Mahon FX, Brousset P.

Blood. 2011 May 26;117(21):5719-22. doi: 10.1182/blood-2011-01-333013. Epub 2011 Apr 7.

PMID:
21474671
17.

Wide diversity of PAX5 alterations in B-ALL: a Groupe Francophone de Cytogenetique Hematologique study.

Coyaud E, Struski S, Prade N, Familiades J, Eichner R, Quelen C, Bousquet M, Mugneret F, Talmant P, Pages MP, Lefebvre C, Penther D, Lippert E, Nadal N, Taviaux S, Poppe B, Luquet I, Baranger L, Eclache V, Radford I, Barin C, Mozziconacci MJ, Lafage-Pochitaloff M, Antoine-Poirel H, Charrin C, Perot C, Terre C, Brousset P, Dastugue N, Broccardo C.

Blood. 2010 Apr 15;115(15):3089-97. doi: 10.1182/blood-2009-07-234229. Epub 2010 Feb 16.

PMID:
20160164
18.

Constitutive activation of the DNA damage signaling pathway in acute myeloid leukemia with complex karyotype: potential importance for checkpoint targeting therapy.

Cavelier C, Didier C, Prade N, Mansat-De Mas V, Manenti S, Recher C, Demur C, Ducommun B.

Cancer Res. 2009 Nov 15;69(22):8652-61. doi: 10.1158/0008-5472.CAN-09-0939. Epub 2009 Oct 20.

Supplemental Content

Support Center